PLOS ONE

1	High prevalence and risk factors of transmission of hepatitis delta virus in
2	pregnant women in the Center Region of Cameroon

- 3
- 4 Juliette-Laure Ndzie Ondigui^{1,2}, Email : <u>njulielaure@gmail.com</u>
- 5 Nadège Mafopa Goumkwa², Email : <u>g.m.nadege@gmail.com</u>
- 6 Cindy Lobe^{2,3}, Email: <u>lobecindy@hotmail.com</u>
- 7 Brigitte Wandji⁴, Email: <u>wandji.brigitte@yahoo.com</u>
- 8 Patrick Awoumou^{5,2}, Email: <u>patrick26lebon@gmail.com</u>
- 9 Prisca Voussou Djivida⁵, Email : <u>djividaprisca@yahoo.fr</u>
- 10 Puinta Peyonga⁵, Email : <u>puipen@yahoo.com</u>
- 11 Solange Manju Atah⁶ Email : <u>solangeneh36@gmail.com</u>
- 12 Vivian Verbe⁷, Email : <u>visale@yahoo.com</u>
- 13 Rachel Kamgaing Simo², Email: <u>r.kamgaing@yahoo.it</u>
- 14 Sylvie Agnès Moudourou², Email : <u>sylvie.moudourou@gmail.com</u>
- 15 Ana Gutierrez⁹, Email : <u>anagutiaci@yahoo.es</u>
- 16 Rosi Garcia⁹, Email : <u>rosi.acibikop@gmail.com</u>
- 17 Isabelle Fernandez⁹, Email : <u>i.fernandez@esclavasaci.es</u>
- 18 Sara Honorine Riwom Essama¹, Email : <u>sarariwom@yahoo.fr</u>
- 19 Robinson Mbu^{4,10}, Email : <u>robinsonmbu@gmail.com</u>
- 20 Judith Torimiro^{2, 5*}, Email: jn.torimiro@gmail.com
- 21
- *1-Department of Microbiology, Faculty of Sciences, University of Yaoundé 1, Yaounde, Cameroon;*
- 24 2- "Chantal BIYA" International Reference Center for research on HIV/AIDS prevention and
 25 management (CIRCB), Yaounde, Cameroon;
- 26 *3- Department of Food Science and Nutrition, National School of Agro-Industrial Sciences,*
- 27 University of Ngaoundere, Ngaoundere, Cameroon;
- 28 4- Yaoundé Gyanecology Obstetrics and Paediatrics Hospital, Yaounde, Cameroon;
- 5- Department of Biochemistry, Faculty of Medicine and Biomedical Sciences, University of
 Yaounde 1, Yaounde, Cameroon;
- 6-Department of Public Health, Faculty of Medicine and Biomedical Sciences, University of NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
 Yaounde 1, Yaounde, Cameroon;

PLOS ONE

- 33 7-Cité Verte District Hospital, Yaounde, Cameroon;
- 34 8- Biyem-Assi District Hospital, Yaounde, Cameroon
- 35 9- Bikop Catholic Health Center, Bikop, Cameroon
- 36 10- Department of Gynecology/Obstetrics, Faculty of Medicine and Biomedical Sciences,
- 37 University of Yaounde 1, Yaounde, Cameroon
- 38 Authors Contributions
- 39 Designed the study: Judith Torimiro, Robinson Mbu, Sara Honorine Riwom Essama, Juliette-
- 40 Laure Ndzie Ondigui; Collected the data: Judith Torimiro, Juliette-Laure Ndzie Ondigui,
- 41 Brigitte Wandji, Patrick Awoumou, Puinta Peyong, Prisca Voussou Djivida, Vivian Verbe,
- 42 Eveline Tincho Foguem, Rachel Kamgaing Simo, Sylvie Agnès Moudourou, Ana Gutierrez,
- 43 Rosi Garcia, Isabelle Fernandez; Analyzed and interpreted the data: Juliette-Laure Ndzie
- 44 Ondigui, Nadège Mafopa Goumkwa, Cindy Lobe, Judith Torimiro; Initiated and drafted the
- 45 manuscript: Juliette-Laure Ndzie Ondigui, Nadège Mafopa Goumkwa, Judith Torimiro;
- 46 *Revised the manuscript:* all the authors read and approved the final manuscript.
- 47 ***Corresponding author:**
- 48 Judith Torimiro
- 49 Email: jn.torimiro@gmail.com
- 50
- 51
- 52
- 53

54

- 56
- 57
- 58
- 59
- 60
- 61
- 62
- ---
- 63

PLOS ONE

64 ABSTRACT

Background: Hepatitis B virus (HBV) and hepatitis delta virus (HDV) co-infection has been described as the most severe form of viral hepatitis, and both can be co-transmitted from mother-to-child. A seroprevalence of 4.0% of HDV infection was reported in pregnant women in Yaoundé, and 11.9% in the general population in Cameroon. Our objective was to describe the rate of HDV infection in pregnant women and to determine risk factors associated with mother-to-child transmission of HDV.

Materials and Methods: A cross-sectional, descriptive study was conducted from January 71 2019 to July 2022 among pregnant women attending antenatal contacts in seven health 72 structures in the Centre Region of Cameroon. A consecutive sampling (non-probability 73 74 sampling) was used to select only women of age over 21 years, who gave a written informed consent. Following an informed consent, an open-ended questionnaire was used for a 75 Knowledge, Attitude and Practice (KAP) survey of these women, and their blood specimens 76 collected and were screened for HBsAg, anti-HIV and anti-HCV antibodies by rapid tests and 77 78 ELISA. HBsAg-positive samples were further screened for HBeAg, anti-HDV, anti-HBs, and anti HBc antibodies by ELISA, and plasma HDV RNA load measured by RT-qPCR. 79

Results: Of 1992 pregnant women, a rate of 6.7% of HBsAg (134/1992) with highest rate in 80 the rural areas, and 3.9% of hepatitis vaccination rate were recorded. Of 134, 44 (32.3%) were 81 anti-HDV antibody-positive, and 47.6% had detectable RNA viraemia. Two women of 44 anti-82 HDV-positive cases (4.5%) were co-infected with HBV and HCV, while 5 (11.4%) with HIV 83 and HBV. Multiple deliveries, the presence of tattoos and/or scarifications were significantly 84 statistically associated with the presence of anti-HDV antibodies. Of note, 80% of women with 85 negative HBeAg and positive anti-HBe serological profile, had plasma HDV RNA load of more 86 than log 3.25 (>10.000 copies/ml). 87

88 Conclusion

These results show an intermediate rate of HDV infection among pregnant women with high level of HDV RNA viremia, which suggest an increased risk of vertical and horizontal cotransmission of HDV.

92

93 Keywords: risk factors, transmission, hepatitis delta virus, pregnancy

PLOS ONE

94 Introduction

Hepatitis B virus (HBV) is the aetiologic agent of hepatitis B. The WHO estimates that 296 million people were living with chronic hepatitis B in 2019 with 1.5 million new infections each year[1], whereas Hepatitis delta virus (HDV) affects nearly 5% of people with chronic hepatitis B worldwide[1]. HDV requires the presence of HBV in order to replicate [2-4] in coinfection or super-infection causing the most serious form of chronic viral hepatitis, given its more rapid progression to hepatocellular carcinoma and death [5-8]. It is also worth noting, the low HBV vaccination rate among pregnant women in Cameroon of less than 2.5% [9].

102 HBV and HDV can be transmitted through skin lesions (injection, scarification, tattooing), contact with infected blood or blood products, but mostly they are co-transmitted through sexual 103 intercourse and from mother-to-child [10]. Therefore, pregnant women are an index population 104 for both vertical and horizontal transmission of HBV and HDV. However, certain practices 105 favour the transmission of HBV in the Centre Region of Cameroon. They include poor 106 accessibility to healthcare, low rate of vaccination, cultural and traditional beliefs, low rate of 107 condom use, high rate of early age of first sexual intercourse, low rate of official marriage, high 108 rate of home delivery, poor link to prevention of mother-to-child transmission (PMTCT) 109 activities, and to other maternal-infant disease prevention efforts in Cameroon. 110

HBV/HDV co-transmission from mother-to-child has been described [11, 12]. It is an event 111 that seems rare but remains possible and the risk could increase with high level of plasma load 112 of HBV DNA and HDV RNA in the pregnant woman [13-15], in individuals with multiple 113 sexual partners and/or with scarification [16]. Vaccination against hepatitis B is an effective 114 strategy to prevent HDV infection. Therefore, scaling-up the national vaccination programme 115 against hepatitis B in the general population, could lead to a drop in the incidence of hepatitis 116 D worldwide. In 2018, it was reported that 83.3% of pregnant women attending ANC in 117 Yaounde, Cameroon, knew that vaccination against HBV infection is a method of prevention, 118 and 47.1% knew that HBV could be transmitted from mother-to-child. However, only 2.5% 119 120 had received three doses of the hepatitis B vaccine [9, 17]. In Cameroon the seroprevalence of HBV (HBsAg) in the general population is 11.2%, about two to three times higher than that of 121 the human immunodeficiency virus (HIV) of 3.4% [18, 19]. In 2021, the Cameroon Ministry 122 of Public Health reported a seroprevalence among pregnant women at first trimester of 5.0% in 123 the Centre Region where this study was carried out against 8.63% of national prevalence [20]. 124 In addition, in Central Africa, HDV seroprevalence is estimated at 25.64% in the general 125 population [7], compared to 46.73% in Cameroon in 2018 [21]. 126

PLOS ONE

Low hepatitis B vaccination coverage in the sexually active population, and lack of recent epidemiological data on HDV in pregnant women, show that the general population in Cameroon is at risk of continuous spread of HBV and HDV from mother-to-child and horizontally. Thus, our specific objectives were to determine the rates of HDV infection and factors associated with risk of HDV infection among pregnant women.

Materials and methods

133 Study design, enrollment procedure and eligibility criteria

A cross-sectional study was conducted from January 2019 to July 2022 in a tertiary hospital, five District hospitals, and one rural Health Center in the Center Region of Cameroon, among pregnant women attending ANC. A total of 1992 pregnant women of age over 21 years were enrolled (Figure 1) from an anticipated 1475 participants deduced from a statistical formula shown below [22] which is commonly used to determine the minimum sample size in medical studies:

140 $n = (Z\alpha)2 p (1-p)/d2$

141 where:

142 $Z\alpha$ = standard normal variate (1.96 for a 95% confidence interval);

143 p= prevalence of HDV among pregnant women in Cameroon (4.0) [9];

144 d = precision of the estimate (0.01).

Substituting the figures in the above formula yields 1475.2 (nearest whole number). Thus, aminimum of 1475 participants was required.

Data collection took place in 3 stages. Before enrolling the participants, a group sensitization 147 at the hospital or Health Center was conducted to raise awareness on hepatitis B transmission 148 and prevention, hepatitis B and pregnancy, the importance of HBV screening and the purpose 149 of the study. Thereafter, 1992 subjects who were willing to be part of the study, were 150 administered a Consent Form, and upon their consent, a questionnaire with open-ended 151 questions was administered to collect personal and socio-demographic data, their knowledge, 152 attitude and practices with respect to hepatitis B. Some women who took part in the sensitization 153 campaign were not enrolled in the study because they had to have the opinion of their partners, 154 or did not give any reason. 155

PLOS ONE

A consecutive sampling (non-probability sampling) was used to select only pregnant women of age over 21 years, who gave a written informed consent. In order to avoid any confusion and to preserve the anonymity of the participants, each participant was assigned a code that allowed us to link each questionnaire to its corresponding blood specimen, while another Register of the ANC used only by hospital staff was established to link the subjects to their results. This same code was used throughout the analysis in the laboratory and the results were linked to the identity of the subject by the hospital staff and not by the research team.

163 Laboratory procedures

After completing the questionnaire, 5 ml of blood was drawn from 1992 subjects into a tube 164 containing ethylene-diamine-tetra-acetic acid (EDTA), processed and the plasma tested for 165 HBsAg, anti-HIV and anti-HCV antibodies using rapid diagnostic tests (RDT. ABON. 166 Determine HIV1/2 and KHB Diagnostic kit for HIV antibodies 1 + 2) and ELISA (Murex 167 HBsAg, and Murex HCV Ab), following the manufacturer's instructions. Furthermore, the 168 HBsAg-positive samples were tested by ELISA for other HBV infection biomarkers: anti-HBs, 169 anti-HBc, HBeAg, and anti-HBe. Positive and negative plasma controls were run alongside 170 each test, following the National Testing Algorithms for these viruses in Cameroon. 171

ELISA was performed to detect anti-HDV antibodies in 134 plasma samples using the ETI-172 DELTA-IGMK-2 kit (Dia.Pro Diagnostic Bioprobes srl, Italy). Quantification of HDV RNA 173 (viral RNA load) by real-time qRT-PCR (Eurobioplex HDV Kit, Eurobio Scientific, France) 174 was performed using 34 anti-HDV positive plasma samples. All serologic results were made 175 available to the women within two weeks after specimen collection. The rapid test results were 176 confirmed by two technicians and the samples with borderline results, were further analyzed by 177 ELISA. On the other hand, plasma HDV RNA load was quantified by qRT-PCR commercial kit that 178 detects all 8 main genotypes of HDV, with a lower limit of detection of 100IU/mL. Through these 179 analyses, the subjects that were infected with HBV and/or HDV, were identified. These results 180 were linked to the reported answers given by each subject in relation to their knowledge on 181 modes of transmission and prevention of HBV, their attitude towards prevention of HBV 182 infection such as vaccination and unprotected sex, as well as their practices that predisposes 183 184 them to acquiring HBV and/or HDV.

All women who tested positive for HBsAg were offered post-test counselling on their status, modes of hepatitis B transmission, need for testing of close contacts for hepatitis B, and vaccination of baby within the first twenty four hours of life against hepatitis B. They were then

PLOS ONE

referred for clinical evaluation and management to a gastroenterologist, and those who werenegative for HBsAg were advised to get vaccinated if not yet.

190 Statistical analysis

- 191 Data collected was regularly checked, corrected, recorded and processed using IBM.SPSS.
- 192 Statistics.v20 software, while ensuring anonymity with the use of subject registration code.
- 193 Frequencies of qualitative data were estimated as means. Using internal negative and positive
- 194 controls in each run, a cycle threshold (Ct) of \leq 35 was considered positive, and Ct > 35 and \leq
- 45 was considered a non-quantifiable positive result. Using a standard curve drawn from
- 196 standards provided by the manufacturer, the HDV RNA load was extrapolated to copies/mL
- which was then multiplied by a factor (0.18) to convert into IU/mL. The analysis of the
- 198 relationship between the prevalence and the different characteristics of the sample was done
- by logistic regression. Using the Pearson Chi-2 test, the factors associated with HBV and
- HDV infection, were determined with p values <0.05 considered statistically significant. Ten
- samples with missing data were not included in the analysis.

202 Ethical considerations

203 The study was conducted in accordance with the fundamental principles of the Declaration of Helsinki, with administrative and ethical approval from health facilities and laboratories, as 204 well as the National Ethics Committee for Human Health Research in Cameroon (N° 205 2018/06/1150/L/CNERSH/SP), respectively. A written informed consent was obtained from all 206 participants, data was recorded using unique identifiers to ensure confidentiality, and laboratory 207 results were returned to participants for potential benefits in their clinical management. The 208 subjects positive for HBsAg antigen were referred to a gastroenterologist and those HBsAg-209 negative were advised to be vaccinated if not yet. 210

211 **Results**

Socio-demographic parameters and Knowledge, Attitude and Practices of pregnant women

Overall, 1992 pregnant women were tested for HBsAg, with a mean age of 27.53 ± 5.68 years. The average gestational age was 17 ± 6 weeks, with a majority of the women at the second trimester pregnancy. One thousand nine hundred and thirteen (1913) women have never received the hepatitis B vaccine, but 56 had received three doses of the vaccine (2.8%) (Table 1). One thousand six hundred and twenty seven (1627) women were screened for the first time

PLOS ONE

for HBsAg during this study (81.7%). In the group of HBsAg-positive women, 53(39.9%) women were in their first pregnancy, 75 (56.4%) lived with a partner, 37 (27.8%) knew their partner's hepatitis B status and 5.4% (2/37) of their partners were positive for HBsAg, 15 (11.3%) had already been tattooed or scarified and 21 (15.7%) had a history of surgery.

223 Prevalence of HDV and HBV Infection markers

Of 1992 pregnant women tested for HBsAg, 133 were positive (6.7%) while 9.8% of women 224 in the third trimester were HBsAg-positive, and 9.9% of them live in the rural area. Of these, 225 42 samples were positive for anti-HDV antibodies by serology, with 62.5% with detectable 226 plasma HDV RNA. Meanwhile, rates of 9.0%, 79.7% and 94.0% for HBeAg, anti-HBe and 227 anti-HBc, respectively, was recorded for the HBsAg-positive specimens. Table 2 shows the 228 distribution of serological markers of hepatitis B infection (HBeAg, HBeAb and HBcAb) as a 229 function of the presence of anti-HDV antibodies, indicating that HBeAg was statistically 230 significantly associated with the presence of anti-HDV antibodies (p = 0.008). Two (4.8%) 231 women were co-infected with HCV, HBV and HDV, and 5 (11.9%) with HIV, HBV and HDV. 232 However, HBV/HIV and HBV/HCV co-infections were not associated with anti-HDV 233 234 positivity in this study. In univariate analysis, neither of HIV nor HCV serologic positivity was associated statistically significantly with the presence of anti-HDV antibodies (Table 2). 235

236 237

5 Factors associated with hepatitis delta virus infection

Our study shows that 4 women with more than 5 children were positive for anti-HDV 238 antibodies. In addition, women living with a partner (44.0%) were more exposed than women 239 living alone (16.4%) to be infected with HDV (p=0.001), while 60.0% of women who had been 240 tattooed or scarified had anti-HDV antibodies (p=0.015) (Table 3). Comparing the 241 seroprevalence of HDV antibodies against biomarkers of HBV infection, there was a 242 statistically significant difference with the presence of anti-HBc (p=0.008), anti-HBe (p=0.001) 243 and HBeAg-negative/Anti-HBe+ (p=0.005). Of note, the HBeAg-negative/anti-HBe-positive 244 profile was the most frequently detected amongst those with plasma HDV RNA viral load of 245 246 more than log 3.25 (10.000 copies/mL) (Table 4).

247

248 **Discussion**

We studied the seroprevalence of anti-HDV antibodies and the presence of plasma HDV RNA in 130 HBsAg-positive samples, detected in a sample of 1992 pregnant women collected between January 2019 and July 2022 in seven health structures in the Centre Region of

PLOS ONE

Cameroon. Overall, we observed a seroprevalence of HBsAg of 6.7%. These results are close 252 to those obtained by Torimiro et al in 2018 (6.4%) among pregnant women in Yaoundé, 253 Cameroon [9]. In comparison to other African countries with similar socio-economic and public 254 health contexts, such as Nigeria, Gabon and Burkina Faso, similar prevalence has been reported 255 [23, 24]. We also noted that in our study population the prevalence of HBsAg is higher among 256 pregnant women in rural areas compared to those in urban areas. Other studies conducted in 257 rural areas in Cameroon, have recorded higher prevalence ranging from 7.5% to 13.7% [25-258 259 27].

This moderate to high prevalence of hepatitis B in rural areas in Cameroon could be related to 260 the low level of knowledge about hepatitis B modes of transmission and prevention, and risk 261 262 factors of attitude and practices including idleness and promiscuity. In other words, these are factors that would favour transmission of HDV. Although the efficacy of the hepatitis B vaccine 263 has been proven and has been available since 2005 in the Cameroon EPI [28], this study shows 264 that vaccination coverage remains very low among women of child-bearing age, which 265 contributes in keeping the pool of index infected sub population on the increase. It is therefore 266 not unusual to detect the high prevalence of HDV infection in pregnant women in the Centre 267 268 Region of Cameroon. Since 1991 when the first study on the prevalence of HDV was conducted in Cameroon[29], several studies have been carried out in the general population or among 269 people with particular socio-demographic characteristics such as pygmies. The variations in the 270 prevalence of anti-HDV antibody ranged from 10.5% to 69% [16, 21, 30-32]. On the other 271 hand, very few of these studies have focused on pregnant women who are an index for both 272 horizontal and vertical transmission of HBV and HDV. These studies reported low levels of 273 anti-HDV antibodies in pregnant women of 2.3-4.0% [9, 29]. These values are low compared 274 to the rate of 32.3% anti-HDV antibody prevalence which we obtained in our study. This 275 difference could be due to the fact that the previous studies were conducted in the Yaoundé an 276 urban area, where there are better living conditions, higher level of education, awareness and 277 knowledge of hepatitis B compared to the semi-urban and rural areas that were included in our 278 279 study. In comparison of anti-HDV antibody rates among pregnant women in other African countries such as Benin (11.4%), Mauritania (14.7%), Gabon (15.6%), the Central African 280 Republic (21. 4%)[33-36], our result is higher at 32.3%. 281

Our findings show that the number of children, marital status, presence of tattoos or scarifications and history of surgery are factors associated with the positivity of anti-HDV

PLOS ONE

- antibodies. Besombes and colleagues reported in 2020 that individuals with more than 10 sexual
 casual partners and those who received injections were most at risk of getting HDV [16].
- The rates of HBV serological markers in anti-HDV-positive individuals showed that anti-HBc antibodies and anti-HBe antibodies were statistically associated with anti-HDV positivity in this study. Similarly, a majority of women with the HBeAg-negative/HBeAb-positive
- serological profile, had plasma HDV RNA viral load ranging from 10000 to 35000 copies/mL.
- 290 Limitations of this study include the performance of the test HDV antibody test kit and the lack
- of a national testing algorithm for diagnosis of HDV infection in Cameroon.

292 Conclusion

In conclusion, the results of this study show that in spite of the availability of the hepatitis B vaccine in the EPI in Cameroon, HBV infection is moderately endemic (6.7%) in the Centre Region of Cameroon, while HDV rate is 32.3% among pregnant women. Increasing number of casual sexual partners and high level of HDV viremia, may favour horizontal and vertical cotransmission of HDV in this population. Hence, the need to intensify awareness and control strategies for hepatitis B and D among pregnant women and contribute to the global elimination of hepatitis B.

300 Acknowledgement

- We acknowledge the financial and technical contributions from the Chantal Biya International
 Reference Centre for Research on Prevention and Management of HIV/AIDS to carry out this
 study.
- Funding was provided by the Chantal Biya International Reference Centre for Research on
 Prevention and Management of HIV/AIDS (CIRCB). And the WHO Sasakawa 2019 Health
 Prize to Judith Torimiro.
- 307

308 References

- 309 1. WHO, Key facts on hepatitis B. 2020.
- 310 2. Sawadogo, A., et al., Seroprevalence of hepatitis D virus infection in a population of
- 311 blood donors carrying HBs Antigen at the Bobo-Dioulasso Regional Blood Transfusion
- 312 *Center.* Journal Africain d'Hépato-Gastroentérologie, 2016. **10**(1): p. 31-33.

PLOS ONE

313	3.	Sahin, A., et al., Anti-HDV seroprevalance among patients with previous HBV infection.
314		North Clin Istanb, 2018. 5(2): p. 132-138.
315	4.	Medhat, A., et al., Acute viral hepatitis in pregnancy. Int J Gynaecol Obstet, 1993.
316		40 (1): p. 25-31.
317	5.	Dulger, A.C., et al., High prevalence of chronic hepatitis D virus infection in Eastern
318		Turkey: urbanization of the disease. Arch Med Sci, 2016. 12(2): p. 415-20.
319	6.	A.T. Kabamba, C.M.M., C.M. Nyembo, B.M. Kabamba Et And A.O. Longanga,
320		Hepatitis D seroprevalence among people with chronic hepatitis B in Lubumbashi
321		<i>(DRC)</i> . 2020.
322	7.	Stockdale, A.J., et al., Prevalence of hepatitis D virus infection in sub-Saharan Africa:
323		a systematic review and meta-analysis. Lancet Glob Health, 2017. 5(10): p. e992-e1003.
324	8.	Daw, M.A., et al., The Epidemiology of Hepatitis D Virus in North Africa: A Systematic
325		Review and Meta-Analysis. ScientificWorldJournal, 2018. 2018: p. 9312650.
326	9.	Torimiro, J.N., et al., Rates of HBV, HCV, HDV and HIV type 1 among pregnant women
327		and HIV type 1 drug resistance-associated mutations in breastfeeding women on
328		antiretroviral therapy. BMC Pregnancy Childbirth, 2018. 18(1): p. 504.
329	10.	WHO, Key facts on hepatitis D.2022.
330	11.	Zanetti, A.R., et al., Perinatal transmission of the hepatitis B virus and of the HBV-
331		associated delta agent from mothers to offspring in northern Italy. J Med Virol, 1982.
332		9 (2): p. 139-48.
333	12.	Huang, Y.H., et al., Phylogenetic analysis to document a common source of hepatitis D
334		virus infection in a mother and her child. Zhonghua Yi Xue Za Zhi (Taipei), 1999.
335		62 (1): p. 28-32.
336	13.	Sellier, P., et al., Untreated highly viraemic pregnant women from Asia or sub-Saharan
337		Africa often transmit hepatitis B virus despite serovaccination to newborns. Liver Int,
338		2015. 35 (2): p. 409-16.
339	14.	Sellier, P.O., et al., Hepatitis B Virus-Hepatitis D Virus mother-to-child co-
340		transmission: A retrospective study in a developed country. Liver Int, 2018. 38(4): p.
341		611-618.
342	15.	Yuan, J., et al., Antepartum immunoprophylaxis of three doses of hepatitis B
343		immunoglobulin is not effective: a single-centre randomized study. J Viral Hepat, 2006.
344		13 (9): p. 597-604.
345	16.	Besombes, C., et al., The epidemiology of hepatitis delta virus infection in Cameroon.
346		Gut, 2020. 69(7): p. 1294-1300.

PLOS ONE

Stockdale, A.J., et al., The global prevalence of hepatitis D virus infection: Systematic 17. 347 review and meta-analysis. J Hepatol, 2020. 73(3): p. 523-532. 348 349 18. Bigna, J.J., et al., Seroprevalence of hepatitis B virus infection in Cameroon: a systematic review and meta-analysis. BMJ Open, 2017. 7(6): p. e015298. 350 19. CAMPHIA 2017 population impact assessment of HIV in Cameroon, 2020. 351 Directorate for Disease Control, the E.e.l.P.-D., Monitoring Report on Key Health 20. 352 Indicators in Cameroon in 2019. 2022. 353 21. Butler, E.K., et al., High prevalence of hepatitis delta virus in Cameroon. Sci Rep, 2018. 354 **8**(1): p. 11617. 355 22. Pourhoseingholi, M.A., M. Vahedi, and M. Rahimzadeh, Sample size calculation in 356 357 medical studies. Gastroenterol Hepatol Bed Bench, 2013. 6(1): p. 14-7. 23. Groc, S., et al., High prevalence and diversity of hepatitis B and hepatitis delta virus in 358 Gabon. J Viral Hepat, 2019. 26(1): p. 170-182. 359 24. Lingani, M., et al., The changing epidemiology of hepatitis B and C infections in 360 Nanoro, rural Burkina Faso: a random sampling survey. BMC Infect Dis, 2020. 20(1): 361 362 p. 46. 25. Sone, L.H.E., et al., Prevalence and Identification of Serum Markers Associated with 363 Vertical Transmission of Hepatitis B in Pregnant Women in Yaounde, Cameroon. Int J 364 MCH AIDS, 2017. 6(1): p. 69-74. 365 26. Eyong, E.M., et al., The prevalence of HBsAg, knowledge and practice of hepatitis B 366 prevention among pregnant women in the Limbe and Muyuka Health Districts of the 367 South West region of Cameroon: a three-year retrospective study. Pan Afr Med J, 2019. 368 **32**: p. 122. 369 370 27. Mawouma, A.R.N., et al., [Factors associated with hepatitis B infection in pregnant women at health facilities in the health district of Mokolo/Far North of Cameroon]. Pan 371 Afr Med J, 2022. 41: p. 61. 372 Gatchalian, S., et al., A new DTPw-HBV/Hib vaccine is immunogenic and safe when 373 28. 374 administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth. Hum Vaccin, 2005. 1(5): p. 198-203. 375 376 29. Ndumbe, P.M., Hepatitis D in Yaounde, Cameroon. Apmis, 1991. 99(2): p. 196-8. Noubissi-Jouegouo, L., et al., Evolutionary trends in the prevalence of anti-HDV 30. 377 378 antibodies among patients positive for HBsAg referred to a national laboratory in Cameroon from 2012 to 2017. BMC Res Notes, 2019. 12(1): p. 417. 379

PLOS ONE

380	31.	Luma, H.N., et al., Prevalence and Characteristics of Hepatitis Delta Virus Infection in
381		a Tertiary Hospital Setting in Cameroon. J Clin Exp Hepatol, 2017. 7(4): p. 334-339.
382	32.	Foupouapouognigni, Y., et al., Endemicity and genetic diversity of Hepatitis delta virus
383		among Pygmies in Cameroon, Central Africa. BMC Res Notes, 2022. 15(1): p. 87.
384	33.	Mansour, W., et al., Prevalence, risk factors, and molecular epidemiology of hepatitis
385		B and hepatitis delta virus in pregnant women and in patients in Mauritania. J Med
386		Virol, 2012. 84(8): p. 1186-98.
387	34.	Makuwa, M., et al., Prevalence and genetic diversity of hepatitis B and delta viruses in
388		pregnant women in Gabon: molecular evidence that hepatitis delta virus clade 8
389		originates from and is endemic in central Africa. J Clin Microbiol, 2008. 46(2): p. 754-
390		6.
391	35.	Komas, N.P., et al., Hepatitis B and hepatitis D virus infections in the Central African
392		Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing
393		spread in asymptomatic young adults. PLoS Negl Trop Dis, 2018. 12(4): p. e0006377.
394	36.	De Paschale, M., et al., Prevalence of HBV, HDV, HCV, and HIV infection during
395		pregnancy in northern Benin. J Med Virol, 2014. 86(8): p. 1281-7.

PLOS ONE

397 Table 1: Characteristics of the study population

		HBsAg			
Variables		Negative (%)	Positive (%)	p-value	
Age (years)	15-20	209 (91.2)	19 (8.8)		
Mean = 27 years	21-25	580 (92.2)	49 (7.8)		
	26-30	507 (94.9)	27 (5.1)	0,21	
	31-35	360 (93.0)	27 (7.0)		
	36-40	172 (94.0)	11 (6.0)		
	41-45	31 (100.0)	0 (0)		
Gestational age	1-14	527(92.1)	45(7.9)	0.017*	
(weeks)	15-28	940(94.4)	65(5.6)		
Mean = 18 weeks	29-42	374(90.1)	41(9.9)		
Hepatitis B	Not vaccinated	1779(93.04%)	133(7.0)	0.637	
vaccination	1 Dose	10(100.0%)	0(0)		
	2 Doses	14(100.0%)	0(0)		
	3 Doses	56(0.58%)	0(0)		
Location of health	urban	1169(94.88%)	63(5.1)	0 .016*	
institution/study	semi-urban	263(91.96%)	23(8.0)		
site	rural	427(90.08%)	47(9.9)		

398

399 *. *The Chi-square statistic is significant at the .05 level.*

PLOS ONE

Table 2: Distribution of viral infections (HCV, HDV, and HIV) and serological markers 402 of hepatitis B infection among HBsAg-positive pregnant women 403

		Presence of anti-HDV antibodies			
Serological markers		Negative (%)	Positive (%)	P-value	
Anti-HIV	Negative	80(68.4)	37(31.6)	0.612	
	Positive	8(61.5)	5(38.46)		
Anti-HCV	Negative	88(68.8)	40(31.2)	0.119	
	Positive	0(0)	2(100.0)		
HBeAg	Negative	82(69.5)	36(30.5)	0.169	
	Positive	6(50.0)	6(50.0)		
HBc antibodies	Negative	2(25.0)	6(75.0)	0.008*	
	Positive	86(70.5)	36(29.5)		
HBe antibodies	Negative	9(36.0)	16(64.0)	0.001*	
	Positive	79(75.2)	26(24.8)		
HBeAg-/HBeAb -		8(44.4)	10(55.6)	0.005*	
HBeAg+/HBeAb -		0(0)	6(100.0)		
HBeAg-/HBeAb +		75(75.3)	26(25.7)		
HBeAg+/HBeAb +		5(100.0)	0(0)		

⁴⁰⁴

405

Note 406 +: positive;

407 -: negative;

408 *. The Chi-square statistic is significant at the .05 level.

PLOS ONE

Table 3: Variation in the prevalence of hepatitis delta according to the clinical characteristics of pregnant women

Variable		Presence of anti-HDV antibodies			
		Negative (%)	Positive (%)	p-value	
	15-20	16(84.2)	3 (15.8)	0.50	
Age Group (years)	21-25	31 (66.0)	16 (34.0)	_	
Mean = 26 years	26-30	17 (60.7)	11 (39.3)	_	
_	31-35	18 (69.2)	8 (30.8)	_	
_	36-40	6 (60.0)	4 (40.0)	_	
Gestational age (weeks)	1-14	18 (69.2)	8 (30.2)	0.92	
Mean : 22 (weeks)	15-28	34 (68.0)	16 (32.0)	_	
_	29-42	36 (66.7)	18 (33.3)	_	
Number of life births	0	40 (75.5)	13 (24.5)	0.030	
_	1	26 (72.2)	10 (27.8)	_	
_	2	10 (62.5)	6 (37.5)	_	
	3	11 (55.0)	9 (45.0)	_	
	4	1 (100.0)	0 (0.0)	_	
	5+	0 (0.0)	4 (100.0)	_	
Marital status	life alone	46 (83.6)	9 (16.4)	0.001*	
_	married life	42 (56.0)	33 (44.0)	_	
Knowledge of tattoo	yes	6 (40.0)	9 (60.0)	0.015*	
	no	82 (71.3)	33 (28.7)	_	
History of surgical	yes	19 (90.5)	2 (9.5)	0.015*	
operations	no	69 (63.3)	40 (36.7)		
Knowledge of female	yes	5 (100.0)	0 (00.0)	0.115	
circumcision	no	83 (66.4)	42 (33.6)	-	
Use of alcohol	yes	39 (68.4)	18 (31.6)	0.87	
	no	49 (67.1)	24 (32.9)		
Aware of hepatitis B	no one knows	2 (100.0)	0 (00.0)	0.189	
status of close people	husband	15 (60.0)	10 (40.0)	_	
_	family member	0 (00.0)	2 (100.0)	_	
_	friend	46 (64.8)	25 (35.2)	_	

412

413 *Note*


414 *. *The Chi-square statistic is significant at the .05 level.*

PLOS ONE

416 Table 4: Plasma HDV RNA viral load as a function of the serological profile of HBeAb

417 and HBeAg markers

			HDV RN	A viral load (copies	s/mL)
Serological profile	Not detected	< 15	(15-1000)	(1000-10000)	(10000-35000)
HBeAg-/HBeAb -	5(33.33%)	0(0.0%)	2(40.0%)	2(40.0%)	0(0.0%)
HBeAg+/HBeAb -	1(6.67%)	0(0.0%)	1(20.0%)	0(0.0%)	1(20.0%)
HBeAg-/HBeAb +	9(60.0%)	4(100.0%)	2(40.0%)	3(60.0%)	4(80.0%)
Total	15	4	5	5	5



* Primary health care institution

Figure 1: Map of ten regions of Cameroon.

Figure 1




Figure 2: Diagram showing procedure of screening for HBsAg and antibodies to and RNA of HDV of pregnant women.

Figure 2